Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Feb 19;10:2990. doi: 10.1038/s41598-020-59999-w

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Photoreceptor survival is not affected by long-term ML-265 treatment in vivo. (a) Representative OCT images from baseline (prior to treatment) and DMSO and ML-265 treated eyes after 6 weekly intravitreal injections. OSEL, outer segment equivalent length. (b) Outer retinal thickness as determined by OCT in DMSO and ML-265 treated eyes. Measurements were determined immediately prior to starting 6 weekly intravitreal injections (baseline) and again, one week after the last intravitreal injection (6 weeks). (c) OSEL as determined by OCT in DMSO and ML-265 treated eyes. n ≥ 4 eyes per treatment per time point. (d) Representative hematoxylin and eosin stained retinal sections from DMSO and ML-265 treated eyes after 6 weekly intravitreal injections. ONL, outer nuclear layer; INL, inner nuclear layer. (e) ONL cell counts as a percent of the vehicle-treated (DMSO) retinas. Retinas were harvested one week after the last of 6 weekly intravitreal injections with either DMSO or ML-265. (f) ONL area as a percent of the vehicle-treated (DMSO) retinas. n = 8 eyes per treatment. Mean ± SEM.